Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

详细信息    查看全文

• 作者：Bhumsuk Keam (1) (2)
  Dong-Wan Kim (1) (2)
  Jin Hyun Park (1)
  Jeong-Ok Lee (1)
  Tae Min Kim (1) (2)
  Se-Hoon Lee (1) (2)
  Doo Hyun Chung (3)
  Dae Seog Heo (1) (2)
  
• 关键词：EGFR ; Rare mutation ; Complex mutation ; Gefitinib ; Erlotinib
• 刊名：International Journal of Clinical Oncology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：19
• 期：4
• 页码：594-600
• 全文大小：206 KB
• 参考文献：1. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500 CrossRef
  2. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-139 CrossRef
  3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-57 CrossRef
  4. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-501 CrossRef
  5. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers-and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-3311 CrossRef
  6. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-28 CrossRef
  7. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-388 CrossRef
  8. Wu JY, Yu CJ, Chang YC et al (2011) Effectiveness of tyrosine kinase inhibitors on “uncommon-epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812-821 CrossRef
  9. Pallis AG, Voutsina A, Kalikaki A et al (2007) ‘Classical-but not ‘other-mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97:1560-566 CrossRef
  10. Murray S, Dahabreh IJ, Linardou H et al (2008) Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 3:832-39 CrossRef
  11. Gu D, Scaringe WA, Li K et al (2007) Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28:760-70 CrossRef
  12. De Pas T, Toffalorio F, Manzotti M et al (2011) Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 6:1895-901 CrossRef
  13. Ma F, Sun T, Shi Y et al (2009) Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 66:114-19 CrossRef
  14. Centeno I, Blay P, Santamaria I et al (2011) Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer 11:172 CrossRef
  15. Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105:2070-075 CrossRef
  16. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-0937 CrossRef
  17. Zhang GC, Lin JY, Wang Z et al (2007) Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. Clin Oncol (R Coll Radiol) 19:499-06 CrossRef
  18. Huang SF, Liu HP, Li LH et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-203 CrossRef
  19. Hsieh MH, Fang YF, Chang WC et al (2006) Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer 53:311-22 CrossRef
  20. Hata A, Yoshioka H, Fujita S et al (2010) Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. J Thorac Oncol 5:1524-528 CrossRef
  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-16 CrossRef
  22. Kim YT, Kim TY, Lee DS et al (2008) Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 59:111-18 CrossRef
  23. Wu JY, Wu SG, Yang CH et al (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 14:4877-882 CrossRef
  24. Yokoyama T, Kondo M, Goto Y et al (2006) EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97:753-59 CrossRef
  25. Wu SG, Chang YL, Hsu YC et al (2008) Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 13:1276-284 heoncologist.2008-0093" target="_blank" title="It opens in new window">CrossRef
  26. Su KY, Chen HY, Li KC et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30:433-40 CrossRef
  
• 作者单位：Bhumsuk Keam (1) (2)
  Dong-Wan Kim (1) (2)
  Jin Hyun Park (1)
  Jeong-Ok Lee (1)
  Tae Min Kim (1) (2)
  Se-Hoon Lee (1) (2)
  Doo Hyun Chung (3)
  Dae Seog Heo (1) (2)
  
  1. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea
  2. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
  3. Department of Pathology, Seoul National University Hospital, Seoul, Korea
  
• ISSN：1437-7772

文摘

Background There are many complex and rare mutations in the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical mutations of L858R and exon 19 deletional mutation. The purpose of this study was to investigate the clinical significance of rare and complex mutations, and the efficacy of EGFR tyrosine kinase inhibitors (TKIs). Methods We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. Exons 18 to 21 of EGFR were analyzed by PCR and subjected to direct sequencing methods. Results Of 306 patients who had EGFR mutation, 24 patients (7.3?%) had complex mutations. The frequency of rare mutations was 10.3?%. Four groups were categorized [group A (N?=?269): classical mutation alone; group B (N?=?16): complex mutation with classical mutation; group C (N?=?16): rare mutation alone or complex mutation with rare mutation; group D (N?=?5); classical mutation with T790M]; the response rate (RR) to TKI was significantly different between each group (RR?=?74.8?% in group A vs. 68.8?% in group B vs. 25.0?% in group C vs. 80.0?% in group D, P?P? Conclusions NSCLC patients harboring rare mutations did not show consistent and favorable responses to EGFR TKI compared with those harboring classical mutations. However, complex mutations with classical mutations showed similar treatment efficacy toward EGFR TKI to that with classical mutations alone.